文献速递甲状腺疾病

基于人工智能的无CT定量甲状腺SPECT:前瞻性多中心非劣效性临床试验

CT-Free Quantitative Thyroid SPECT Based on Artificial Intelligence: A Prospective Multicenter Noninferiority Clinical Trial.
PubMed 文献 · Thyroid · 2026-04-07

这项前瞻性多中心非劣效性试验纳入152例甲状腺毒症患者,评估AI驱动的无CT甲状腺SPECT能否替代传统SPECT/CT。无CT SPECT对Graves病诊断准确率为86.2%,传统SPECT/CT为85.5%,准确率差异置信区间下限为-3.0%,满足非劣效界值-10%。无CT方案还将辐射暴露从3.34 mSv降至2.22 mSv(降低33.5%),并更快自动生成TcTU值(40分钟 vs 4分钟)。

要点

  • AI无CT甲状腺SPECT对Graves病诊断非劣效于传统SPECT/CT
  • 无CT方案辐射暴露降低33.5%,从3.34 mSv降至2.22 mSv
  • 无CT SPECT自动生成TcTU值更快(40分钟 vs 4分钟)

核心结论

  • AI驱动的无CT甲状腺SPECT对甲状腺毒症的诊断性能非劣效于传统SPECT/CT,同时降低辐射暴露和分析时间。

研究设计与样本

  • 前瞻性多中心非劣效性临床试验(KCT0008387),纳入来自三家三级转诊医院的152例甲状腺毒症患者。
  • 使用预训练AI模型仅基于SPECT图像生成锝甲状腺摄取(TcTU)值,并与传统SPECT/CT衍生的TcTU比较。
  • 主要终点为Graves病诊断准确率,非劣效界值为置信区间下限大于-10%。

主要发现

  • 152例患者中,84例为Graves病,45例为不确定性疾病,23例为甲状腺炎。
  • 无CT SPECT对Graves病诊断准确率为86.2%,传统SPECT/CT为85.5%,准确率差异置信区间下限为-3.0%。
  • 对甲状腺炎和抗甲状腺药物(ATD)处方的准确率差异置信区间下限分别为-7.4%和-3.2%。
  • 省略CT使辐射暴露从3.34 mSv降至2.22 mSv,降低33.5%。
  • 无CT SPECT自动生成TcTU值比SPECT/CT更快(40分钟 vs 4分钟)。

关键数值与推荐

  • 非劣效性定义为准确率差异的置信区间下限大于-10%。
  • Graves病诊断准确率:无CT SPECT 86.2% vs 传统SPECT/CT 85.5%,差异置信区间下限-3.0%。
  • 甲状腺炎诊断准确率差异置信区间下限-7.4%。
  • ATD处方预测准确率差异置信区间下限-3.2%。
  • 辐射暴露:无CT SPECT 2.22 mSv vs SPECT/CT 3.34 mSv。

临床怎么用

  • 对于甲状腺毒症患者,可考虑使用AI无CT甲状腺SPECT替代传统SPECT/CT进行Graves病鉴别诊断。
  • 该方案可减少患者辐射暴露并缩短TcTU值生成时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hybrid single-photon emission computed tomography (SPECT)/computed tomography (CT) is used for the differential diagnosis of thyrotoxicosis, but its dependence on CT and complex analysis remains debated. This study evaluated whether CT-free thyroid SPECT using artificial intelligence (AI) could substitute for conventional SPECT/CT. METHODS: This prospective multicenter noninferiority clinical trial (KCT0008387) included 152 patients with thyrotoxicosis from three tertiary referral hospitals. A pretrained AI model generated technetium thyroid uptake (TcTU) values using SPECT images without CT. These values were compared with TcTU derived from conventional SPECT/CT. The primary endpoint was diagnostic accuracy for Graves' disease. Noninferiority was defined as a lower confidence interval (CI) limit greater than -10%. Secondary endpoints included diagnostic accuracy for destructive thyroiditis and prediction of antithyroid drug (ATD) prescription within one month. RESULTS: Among 152 patients, 84 had Graves' disease, 45 had indeterminate disease, and 23 had thyroiditis. For Graves' disease, CT-free SPECT demonstrated 86.2% accuracy compared with 85.5% for conventional SPECT/CT. The lower bound of the CI of the accuracy difference was -3.0%, meeting the prespecified noninferiority margin. For thyroiditis and ATD prescription, the lower bounds were -7.4% and -3.2%, respectively. Omission of CT resulted in a 33.5% reduction of radiation exposure from 3.34 mSv to 2.22 mSv, and CT-free SPECT automatically generated TcTU values more quickly than SPECT/CT (40 minutes vs. 4 minutes). CONCLUSIONS: CT-free SPECT using AI demonstrated noninferior diagnostic performance for thyrotoxicosis compared with conventional hybrid imaging while reducing radiation exposure and analysis time. TRIAL REGISTRATION: https://cris.nih.go.kr (KCT0008387).

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Chung HW, Cho SG, Oh D, et al. CT-Free Quantitative Thyroid SPECT Based on Artificial Intelligence: A Prospective Multicenter Noninferiority Clinical Trial. Thyroid. 2026. PMID: 41944102. doi:10.1177/10507256261440401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。